Quarterly report pursuant to Section 13 or 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.23.1
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended
Mar. 17, 2023
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue   $ 605,844 $ 388,993  
Research and development expenses   595,276 1,101,399  
Prepaid Expense and Other Assets, Current   876,539   $ 556,094
Revenues   605,844 388,993  
Research And Development Expenses [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Accrued expenses and other current liabilities   40,000    
Collaborative Agreements [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenues   0 0  
Takeda [Member] | Royalty Revenue [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue   600,000 $ 400,000  
Catalent Pharma Solutions [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development expenses   1,000    
Prepaid Expense and Other Assets, Current   400,000   $ 300,000
Scripps Research [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development expenses $ 938,000      
Initial payment for research 78,000      
Monthly payment $ 78,000      
Scripps Research [Member] | Scripps Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development expenses   $ 0